
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Evaluating drug targets through human loss-of-function genetic variation
Eric Vallabh Minikel, Konrad J. Karczewski, Hilary C. Martin, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 459-464
Open Access | Times Cited: 160
Eric Vallabh Minikel, Konrad J. Karczewski, Hilary C. Martin, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 459-464
Open Access | Times Cited: 160
Showing 1-25 of 160 citing articles:
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski, Laurent C. Francioli, Grace Tiao, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 434-443
Open Access | Times Cited: 7949
Konrad J. Karczewski, Laurent C. Francioli, Grace Tiao, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 434-443
Open Access | Times Cited: 7949
The mutational constraint spectrum quantified from variation in 141,456 humans
Konrad J. Karczewski, Laurent C. Francioli, Grace Tiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 1045
Konrad J. Karczewski, Laurent C. Francioli, Grace Tiao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access | Times Cited: 1045
Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Emily A. King, J. Wade Davis, Jacob F. Degner
PLoS Genetics (2019) Vol. 15, Iss. 12, pp. e1008489-e1008489
Open Access | Times Cited: 517
Emily A. King, J. Wade Davis, Jacob F. Degner
PLoS Genetics (2019) Vol. 15, Iss. 12, pp. e1008489-e1008489
Open Access | Times Cited: 517
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials
E. Elizabeth Patton, Leonard I. Zon, David M. Langenau
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 8, pp. 611-628
Open Access | Times Cited: 361
E. Elizabeth Patton, Leonard I. Zon, David M. Langenau
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 8, pp. 611-628
Open Access | Times Cited: 361
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Joseph D. Szustakowski, Suganthi Balasubramanian, Erika Kvikstad, et al.
Nature Genetics (2021) Vol. 53, Iss. 7, pp. 942-948
Open Access | Times Cited: 337
Joseph D. Szustakowski, Suganthi Balasubramanian, Erika Kvikstad, et al.
Nature Genetics (2021) Vol. 53, Iss. 7, pp. 942-948
Open Access | Times Cited: 337
Systems biology in cardiovascular disease: a multiomics approach
Abhishek Joshi, Marieke Rienks, Konstantinos Theofilatos, et al.
Nature Reviews Cardiology (2020) Vol. 18, Iss. 5, pp. 313-330
Closed Access | Times Cited: 200
Abhishek Joshi, Marieke Rienks, Konstantinos Theofilatos, et al.
Nature Reviews Cardiology (2020) Vol. 18, Iss. 5, pp. 313-330
Closed Access | Times Cited: 200
Transcript expression-aware annotation improves rare variant interpretation
Beryl B. Cummings, Konrad J. Karczewski, Jack A. Kosmicki, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 452-458
Open Access | Times Cited: 176
Beryl B. Cummings, Konrad J. Karczewski, Jack A. Kosmicki, et al.
Nature (2020) Vol. 581, Iss. 7809, pp. 452-458
Open Access | Times Cited: 176
From variant to function in human disease genetics
Tuuli Lappalainen, Daniel G. MacArthur
Science (2021) Vol. 373, Iss. 6562, pp. 1464-1468
Closed Access | Times Cited: 121
Tuuli Lappalainen, Daniel G. MacArthur
Science (2021) Vol. 373, Iss. 6562, pp. 1464-1468
Closed Access | Times Cited: 121
Association of Antihypertensive Drug Target Genes With Psychiatric Disorders
Solal Chauquet, Zhihong Zhu, Michael O’Donovan, et al.
JAMA Psychiatry (2021) Vol. 78, Iss. 6, pp. 623-623
Open Access | Times Cited: 110
Solal Chauquet, Zhihong Zhu, Michael O’Donovan, et al.
JAMA Psychiatry (2021) Vol. 78, Iss. 6, pp. 623-623
Open Access | Times Cited: 110
From target discovery to clinical drug development with human genetics
Katerina Trajanoska, Claude Bhérer, Daniel Taliun, et al.
Nature (2023) Vol. 620, Iss. 7975, pp. 737-745
Closed Access | Times Cited: 98
Katerina Trajanoska, Claude Bhérer, Daniel Taliun, et al.
Nature (2023) Vol. 620, Iss. 7975, pp. 737-745
Closed Access | Times Cited: 98
Accurate rare variant phasing of whole-genome and whole-exome sequencing data in the UK Biobank
Robin J. Hofmeister, Diogo M. Ribeiro, Simone Rubinacci, et al.
Nature Genetics (2023) Vol. 55, Iss. 7, pp. 1243-1249
Open Access | Times Cited: 93
Robin J. Hofmeister, Diogo M. Ribeiro, Simone Rubinacci, et al.
Nature Genetics (2023) Vol. 55, Iss. 7, pp. 1243-1249
Open Access | Times Cited: 93
Refining the impact of genetic evidence on clinical success
Eric Vallabh Minikel, Jeffery L. Painter, Coco Chengliang Dong, et al.
Nature (2024) Vol. 629, Iss. 8012, pp. 624-629
Open Access | Times Cited: 88
Eric Vallabh Minikel, Jeffery L. Painter, Coco Chengliang Dong, et al.
Nature (2024) Vol. 629, Iss. 8012, pp. 624-629
Open Access | Times Cited: 88
RNA interference in the era of nucleic acid therapeutics
Vasant Jadhav, Akshay Vaishnaw, Kevin Fitzgerald, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 74
Vasant Jadhav, Akshay Vaishnaw, Kevin Fitzgerald, et al.
Nature Biotechnology (2024)
Closed Access | Times Cited: 74
Mendelian inheritance revisited: dominance and recessiveness in medical genetics
Johannes Zschocke, Peter H. Byers, Andrew O.M. Wilkie
Nature Reviews Genetics (2023) Vol. 24, Iss. 7, pp. 442-463
Closed Access | Times Cited: 52
Johannes Zschocke, Peter H. Byers, Andrew O.M. Wilkie
Nature Reviews Genetics (2023) Vol. 24, Iss. 7, pp. 442-463
Closed Access | Times Cited: 52
Efferocytosis in atherosclerosis
Shaunak Adkar, Nicholas J. Leeper
Nature Reviews Cardiology (2024) Vol. 21, Iss. 11, pp. 762-779
Closed Access | Times Cited: 33
Shaunak Adkar, Nicholas J. Leeper
Nature Reviews Cardiology (2024) Vol. 21, Iss. 11, pp. 762-779
Closed Access | Times Cited: 33
Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor
Edwin N. Neumann, Tessa M. Bertozzi, Elaine Wu, et al.
Science (2024) Vol. 384, Iss. 6703
Closed Access | Times Cited: 22
Edwin N. Neumann, Tessa M. Bertozzi, Elaine Wu, et al.
Science (2024) Vol. 384, Iss. 6703
Closed Access | Times Cited: 22
In vivo base editing extends lifespan of a humanized mouse model of prion disease
Meirui An, Jessie R. Davis, Jonathan M. Levy, et al.
Nature Medicine (2025)
Open Access | Times Cited: 2
Meirui An, Jessie R. Davis, Jonathan M. Levy, et al.
Nature Medicine (2025)
Open Access | Times Cited: 2
Unique roles of rare variants in the genetics of complex diseases in humans
Yukihide Momozawa, Keijiro Mizukami
Journal of Human Genetics (2020) Vol. 66, Iss. 1, pp. 11-23
Open Access | Times Cited: 129
Yukihide Momozawa, Keijiro Mizukami
Journal of Human Genetics (2020) Vol. 66, Iss. 1, pp. 11-23
Open Access | Times Cited: 129
Exploring human genomic diversity with gnomAD
Linda Koch
Nature Reviews Genetics (2020) Vol. 21, Iss. 8, pp. 448-448
Open Access | Times Cited: 106
Linda Koch
Nature Reviews Genetics (2020) Vol. 21, Iss. 8, pp. 448-448
Open Access | Times Cited: 106
Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints
Eric Vallabh Minikel, Hien Zhao, Jason Le, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. 19, pp. 10615-10631
Open Access | Times Cited: 98
Eric Vallabh Minikel, Hien Zhao, Jason Le, et al.
Nucleic Acids Research (2020) Vol. 48, Iss. 19, pp. 10615-10631
Open Access | Times Cited: 98
Towards a treatment for genetic prion disease: trials and biomarkers
Sonia M. Vallabh, Eric Vallabh Minikel, Stuart L. Schreiber, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 4, pp. 361-368
Closed Access | Times Cited: 76
Sonia M. Vallabh, Eric Vallabh Minikel, Stuart L. Schreiber, et al.
The Lancet Neurology (2020) Vol. 19, Iss. 4, pp. 361-368
Closed Access | Times Cited: 76
An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues
Ren Zhang, Kezhong Zhang
Progress in Lipid Research (2021) Vol. 85, pp. 101140-101140
Open Access | Times Cited: 66
Ren Zhang, Kezhong Zhang
Progress in Lipid Research (2021) Vol. 85, pp. 101140-101140
Open Access | Times Cited: 66
Using human genetics to improve safety assessment of therapeutics
Keren Carss, Aimée M. Deaton, Alberto del Río-Espínola, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 145-162
Closed Access | Times Cited: 57
Keren Carss, Aimée M. Deaton, Alberto del Río-Espínola, et al.
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 145-162
Closed Access | Times Cited: 57
Sulforaphane reduces obesity by reversing leptin resistance
Işın Çakır, Pauline Lining Pan, Colleen K. Hadley, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 40
Işın Çakır, Pauline Lining Pan, Colleen K. Hadley, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 40
Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency
Saleh Shekari, Stasa Stankovic, Eugene J. Gardner, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1692-1699
Open Access | Times Cited: 32
Saleh Shekari, Stasa Stankovic, Eugene J. Gardner, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1692-1699
Open Access | Times Cited: 32